piperidines has been researched along with Mycoses* in 12 studies
2 review(s) available for piperidines and Mycoses
Article | Year |
---|---|
Fungal Infections Potentiated by Biologics.
Biologic therapies including monoclonal antibodies, tyrosine kinase inhibitors, and other agents represent a notable expansion in the pharmacotherapy armamentarium in treatment of a variety of diseases. Many of these therapies possess direct or indirect immunosuppressive and immunomodulatory effects, which have been associated with bacterial, viral, and fungal opportunistic infections. Careful screening of baseline risk factors before initiation, targeted preventive measures, and vigilant monitoring while on active biologic therapy mitigate these risks as use of biologics becomes more commonplace. This review compiles reported evidence of fungal infections associated with these agents with a focus on the tumor necrosis factor-α inhibitor class. Topics: Adenine; Antigens, CD; Biological Products; Clinical Trials as Topic; Humans; Mycoses; Piperidines; Tumor Necrosis Factor-alpha | 2020 |
Non-Aspergillus invasive mould infections in patients treated with ibrutinib.
Invasive mould infections (IMIs) are very rare in patients with lymphoid malignancies. However, IMIs, mostly due to Aspergillus species, have been increasingly reported in such patients receiving ibrutinib (IBR). There is paucity of information regarding non-Aspergillus invasive mould infections (NAIMIs) in this setting, OBJECTIVES: To review our recent experience and the published literature on the topic.. We present a case of invasive sinusitis caused by Fusarium in a patient with refractory chronic lymphocytic leukaemia (CLL) who was treated with IBR and review the 12 published cases of NAIMIs during IBR.. Nearly all cases of NAIMIs in the setting of IBR use were encountered in patients with CLL. Mixed fungal infections, brain involvement and late-onset infections were common.. Although rare, NAIMIs should be considered in patients who receive IBR. Topics: Adenine; Aged; Anticarcinogenic Agents; Antifungal Agents; Aspergillosis; Aspergillus; Female; Fungi; Fusariosis; Fusarium; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mucorales; Mycoses; Piperidines | 2020 |
10 other study(ies) available for piperidines and Mycoses
Article | Year |
---|---|
Synthesis, Biological Evaluation, and Structure-Activity Relationships of 4-Aminopiperidines as Novel Antifungal Agents Targeting Ergosterol Biosynthesis.
The aliphatic heterocycles piperidine and morpholine are core structures of well-known antifungals such as fenpropidin and fenpropimorph, commonly used as agrofungicides, and the related morpholine amorolfine is approved for the treatment of dermal mycoses in humans. Inspired by these lead structures, we describe here the synthesis and biological evaluation of 4-aminopiperidines as a novel chemotype of antifungals with remarkable antifungal activity. A library of more than 30 4-aminopiperidines was synthesized, starting from Topics: Antifungal Agents; Aspergillus; Biosynthetic Pathways; Candida; Drug Discovery; Ergosterol; Fungi; Humans; Mucorales; Mycoses; Piperidines; Structure-Activity Relationship | 2021 |
Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection.
Topics: Adenine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mycoses; Piperidines; Pyrazoles; Steroids | 2021 |
Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity.
Topics: Adenine; B-Lymphocytes; Consensus; Humans; Immunosuppressive Agents; Mycoses; Neoplasms; Piperidines | 2020 |
Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
Topics: Adenine; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Mycoses; Piperidines; Pyrazoles | 2020 |
Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns.
Topics: Adenine; Humans; Incidence; Invasive Fungal Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Mycoses; Patients; Piperidines; Pyrazoles; Pyrimidines | 2020 |
High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mycoses; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence | 2019 |
Tofacitinib: raising awareness of mycoses.
Topics: Aged; Arthritis, Rheumatoid; Fingers; Humans; Male; Mycoses; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Synthesis and biological evaluation of triazole derivatives as potential antifungal agent.
A series of triazole antifungal agents with piperidine side chains were designed and synthesized. Results of preliminary antifungal tests against eight human pathogenic fungi in vitro showed that all the title compounds exhibited excellent activities with broad spectrum. Moreover, a molecular model for the binding between compound 12 and the active site of CACYP51 was provided based on the computational docking results. The side chain of the compound 12 is oriented into substrate access channel 2 (FG loop) and forms hydrophobic and van der waals interactions with surrounding hydrophobic residues. The phenyl group of the side chain can interact with the phenyl group of Phe380 through the formation of π-π face-to-edge interaction. Topics: Antifungal Agents; Catalytic Domain; Fungi; Humans; Microbial Sensitivity Tests; Models, Molecular; Mycoses; Piperidines; Sterol 14-Demethylase; Structure-Activity Relationship; Triazoles | 2012 |
[Industrial medical prophylaxis & treatment of mycosis with multifungin].
Topics: Antifungal Agents; Drug Combinations; Humans; Mycoses; Piperidines; Salicylanilides; Salicylates | 1959 |
Fungicidal activity of diphenylpyraline.
Topics: Antifungal Agents; Fungicides, Industrial; Mycoses; Piperidines | 1953 |